7 recruiting. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 7 |
| Phase 2 | 5 | Recruiting 5 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage ASP2767, Sham ASP2767, Prophylactic Regimen A - Glaucoma | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 156 | 2026-10-07 | 2026-10-22 |
| REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension REGN22530 - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 271 | 2026-09-08 | 2026-09-28 |
| Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) ER-100 epigenetic therapy - Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy) | Phase 1 | Recruiting | Life Biosciences Inc. | 18 | 2026-03-02 | 2026-05-19 |
| GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma GVB-2001-high dose, GVB-2001-low dose - Primary Open-Angle Glaucoma (POAG) | Phase 1 / Phase 2 | Recruiting | IVIEW Therapeutics Inc. | 6 | 2025-11-19 | 2026-05-04 |
| Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery TimoD implant, Injector system, Timolol eye drops 0.5% - Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Recruiting | EyeD Pharma | 42 | 2025-06-12 | 2026-07-30 |
| Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting Lignocaine-loaded maltose microneedle array patch, EMLA 5% patch - Glaucoma, Cataract | Phase 1 / Phase 2 | Recruiting | Universiti Kebangsaan Malaysia Medical Centre | 154 | 2025-02-17 | 2025-07-18 |
| Topical Insulin for Glaucoma Insulin, 4 units, Insulin, 20 units, insulin, 4 units twice daily - Glaucoma | Phase 1 | Recruiting | Stanford University | 52 | 2022-04-01 | 2026-10-20 |
Glaucoma, Open-Angle (3) · Cataract (2) · Ocular Hypertension (2) · Optic Nerve Diseases (2) · Eye Diseases (1) · Lens Diseases (1) · Night Blindness, Congenital Stationary, Autosomal Dominant 1 (1) · Retinal Diseases (1)
Eye Diseases (6) · Ocular Hypertension (5) · Cranial Nerve Diseases (2) · Nervous System Diseases (2) · Lens Diseases (1)
Drugs, Investigational (1) · Insulin (1) · Lidocaine, Prilocaine Drug Combination (1) · Transdermal Patch (1)
Astellas Pharma Global Development, Inc. (1) · EyeD Pharma (1) · IVIEW Therapeutics Inc. (1) · Life Biosciences Inc. (1) · Regeneron Pharmaceuticals (1) · Stanford University (1) · Universiti Kebangsaan Malaysia Medical Centre (1)
United States (4) · China (1) · Malaysia (1) · Panama (1)
Jeffrey L Goldberg, MD, PhD (1) · Peirong Lu, MD (1) · Sharon Rosenzweig-Lipson, PhD (1)